Objective The purpose of this study was to determine the influence of different concentration iodine contrast media on enhancement of clear cell renal cell carcinoma (ccRCC) in multiphasic contrast-enhanced MDCT of the kidney. Materials and methods We retrospectively reviewed the contrast-enhanced CT findings in 49 patients with ccRCCs proven postoperative pathology record, examinations were performed in multiple phases of enhancement with a MDCT scanner. According to the concentration of iodine contrast media, 49 patients were randomized into two groups. Group A received 100 mL of 300 mgI/mL and group B 75 mL of 370 mgI/mL. Attenuation values were measured at ccRCCs and the normal renal cortex in each phase (unenhanced, corticomedullary, and nephrographic). Statistical analysis was performed for comparison of the degree of enhancement of ccRCCs and the attenuation differences beween tumor and renal cortex. Results In the corticomedullary phase, the 370 mgI/mL concentration showed significantly higher tumor enhancement than 300 mgI/mL in (p<0.05), and there was however no significant difference in the attenuation differences beween tumor and renal cortex (p＞0.05). In the nephrographic phase there was no significant difference in tumor enhancement between the 370 mgI/mL and 370 mgI/mL concentrations (p＞ 0.05), and there was a significant difference in the attenuation differences beween tumor and renal cortex (p<0.05). Conclusion Given equivalent injection rate, the higher iodine concentration leads to a higher corticomedullary phase contrast enhancement of ccRCC and a higher nephrographic phase attenuation differences beween tumor and adjacent renal cortex in MDCT of the the kidney, therefore facilitate visualization of ccRCC in the corticomedullary phase and nephrographic phase.